# US 11,433,092 B2 · Compositions and methods of use for wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,092 B2
- Document ID: US11433092B2
- Status: Granted
- Kind: B2
- Application number: 14/776,084
- Filed: 2014-03-14
- Published: 2016-01-28
- Granted: 2022-09-06
- Earliest claimed: 2013-03-15
- Assignees: Synedgen, Inc.
- Applicants: Synedgen, Inc.
- Inventors: Shenda M. Baker; William P. Wiesmann; Stacy M. Townsend
- Web page: https://patentgrep.com/patent/US11433092B2

## CPC

- A61K 31/726: Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0017: {Non-human animal skin, e.g. pour-on, spot-on}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Described herein are a solution, composition, and kit of poly (acetyl, arginyl) glucosamine (PAAG), methods of making the solution, and method of treating wounds with the solution, the method comprising administering to a subject an effective amount of a solution comprising PAAG, wherein the PAAG when administered topically contacts the wound, thereby treating the wound.

## Claims

### Claim 1

A method of treating a dermal wound in a subject, the method comprising topically administering to the wound an aqueous pharmaceutical gel comprising
hydroxypropyl methylcellulose in an amount of about 0.5% to about 5% by weight per volume of the pharmaceutical gel;
a compound of formula (I)
wherein:
n is an integer between 20 and 6000; and
each R1 is independently selected for each occurrence from hydrogen, acetyl,
wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are
a preservative; and
sterile water, wherein the compound of formula (I) is present in an amount of 0.5% by weight in the pharmaceutical gel;
wherein 21 days after administration of the aqueous pharmaceutical gel, the dermal wound has a thicker epidermis compared to an untreated wound, thereby treating the wound in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is in the family Elephantidae, Rhinocerotidae, or tapirs.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a domesticated animal or pet.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical gel is administered in a volume sufficient to moisten the wound.

### Claim 6 (depends on 1)

The method of claim 1, wherein the wound is caused by a chronic disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the wound is a chronic and non-healing dermal or subdermal wound.

### Claim 8 (depends on 1)

The method of claim 1, wherein the wound is infected with bacteria.

### Claim 9 (depends on 1)

The method of claim 1, wherein the wound is a chronic wound.

### Claim 10 (depends on 1)

The method of claim 1, wherein the wound is an acute wound.

### Claim 11 (depends on 1)

The method of claim 1 wherein the pharmaceutical gel is administered 1, 2, or 3 times a day.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method reduces the healing time or increases the healing rate of the wound.

### Claim 13 (depends on 12)

The method of claim 12, wherein the healing time of the wound is reduced by at least about 10% compared to the healing time of the wound that has not been contacted with the pharmaceutical gel.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method improves the healing of the wound, wherein healing of the wound results in inflammation, and wherein the inflammation resulting from the healing of the wound is reduced.

### Claim 15 (depends on 1)

The method of claim 1, wherein the method decreases the magnitude or extent of scarring.

### Claim 16 (depends on 1)

The method of claim 1, wherein the wound, upon treatment, has a reduced bacterial load.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method comprises rinsing the wound to provide a covering of the wound with a thin layer of a compound of formula (I), wherein the thin layer of a compound of formula (I) reduces the ability of bacteria to bind to the wound relative to a control.

### Claim 18 (depends on 1)

The method of claim 1, wherein the wound is a puncture, abrasion, laceration, incision, scrape, or excision.